Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas
In the study, “Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas,” the researchers used a new drug (Larotrectinib) that is very selective to inhibit the activity of a different gene fusion protein called tropomyosin receptor kinase (TRK). They analyzed data from three different clinical trials and found that there was a durable response in over 50% of patients with sarcomas that had a TRK fusion. This is impactful for patients with these fusions and adds to the rational of sequencing sarcoma patients’ tumors to identify potential therapeutic targets.